Mounjaro in the UK: what it is and how it works

What exactly is Mounjaro, and what's inside the pen?

Mounjaro is the trade name Eli Lilly uses for tirzepatide, its once-weekly injectable medicine. In the UK it comes as a pre-filled disposable device called the KwikPen, and each pen carries four weekly doses. The active ingredient is tirzepatide itself; the rest of the formulation is made up of standard pharmaceutical excipients that keep the solution stable and safe to inject, with the exact list set out in the Mounjaro Patient Information Leaflet.

People searching for what is in Mounjaro sometimes expect a blend of ingredients. It isn't. The single working component is tirzepatide, a molecule engineered to mimic two natural gut hormones. That single-molecule design is part of why it behaves the way it does, and why the medicine is often described by its generic name as much as its brand. If you want the pharmacology in more depth, our page on tirzepatide as the active ingredient unpacks it further.

It's worth being clear about what Mounjaro is not. It isn't a fat-burning supplement, and it isn't sold over the counter. It's a Black Triangle (▼) medicine, which means the MHRA is actively gathering additional safety data on it, and it is prescription-only under UK law. The NHS keeps a plain-English overview on its tirzepatide medicines page, which is a good neutral starting point alongside anything you read here.

A practical detail patients ask about often: the pen lives in the fridge before first use, and there's a limited window it can spend at room temperature. The exact figures matter, so we always point people to the leaflet rather than quoting a number that might drift out of date.

What does Mounjaro actually do in the body?

Mounjaro is a dual GIP and GLP-1 receptor agonist. In plain terms, it switches on two of the gut-hormone receptors your body already uses to manage appetite and blood sugar. GLP-1 medicines act on one of these pathways; Mounjaro acts on both, which is what makes it the only dual-agonist weight-loss medicine licensed in the UK. Diabetes UK and the NHS both describe this dual mechanism in their patient materials.

The day-to-day effect most people notice is reduced hunger. The medicine slows gastric emptying, so food stays in the stomach longer and you feel full sooner and for longer. Many people describe the constant background pull of appetite quietening down, which makes a reduced-calorie diet easier to stick to. It also helps regulate blood sugar, which is why the same molecule is licensed for type 2 diabetes as well as weight management.

None of this happens in isolation. The UK licence is for use alongside a reduced-calorie diet and increased physical activity, not instead of them. The medicine makes the eating changes more achievable; it doesn't replace them. That's a distinction our prescribers return to a lot, because expectations set the tone for how well treatment goes.

If you're curious about the timeline of effects, our guide on how long Mounjaro takes to work covers what to reasonably expect week by week. And because appetite falls on treatment, getting enough protein, fibre and fluid matters more, not less, which is the theme of our advice on eating well while on Mounjaro.

How is Mounjaro dosed, and why does treatment start low?

UK Mounjaro comes in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg. Treatment begins at 2.5mg, and the prescriber then titrates upwards, usually in four-week steps, based on how you tolerate each level and how you respond. The Mounjaro SmPC on the eMC sets out the licensed schedule in full.

The first strength exists to let your system adjust before any therapeutic effect is expected. Starting gently is the single biggest lever for reducing early nausea, which is why nobody begins at a high dose. If you want the reasoning behind the opening strength specifically, our page on the 2.5mg starter pen explains what that first month is really doing, while the 5mg step covers the common second stage.

Beyond that, each rung has its own considerations, and people often want to understand the 7.5mg dose or the higher 10mg dose before they reach them. We'd gently steer you away from planning your own titration schedule, though. When and whether to move up is a clinical judgement your prescriber makes with you, taking tolerance, side effects and progress into account, and the same goes for what to do about a missed dose or a switch.

The KwikPen itself is designed for once-weekly self-injection into the abdomen, thigh or upper arm, rotating the site each time. Our overview of the Mounjaro injection walks through the practicalities. The professional dosing reference, if you want the clinician's-eye view, sits in the BNF entry for tirzepatide.

Who is Mounjaro licensed for in the UK?

The UK licence covers two groups. For weight management, it's for adults with a BMI of 30 or above, or 27 or above where there's at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes, obstructive sleep apnoea or osteoarthritis. It's also licensed for type 2 diabetes. Both uses sit alongside diet and activity changes.

Under UK guidance, the BMI thresholds are set 2.5 kg/m² lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting differences in weight-related health risk. BMI is only ever a starting filter, though. It never guarantees that the medicine is right for you, because a prescriber weighs your full history, not a single number. If you'd like to see where you sit, our BMI guide for Mounjaro talks it through, and the NHS keeps a straightforward BMI calculator you can use in a minute.

There are groups for whom Mounjaro is not suitable. It isn't licensed for anyone under 18. It isn't recommended if you're pregnant, breastfeeding or trying to conceive. A history of medullary thyroid cancer, MEN2, pancreatitis or certain gut conditions needs a proper conversation with a prescriber before treatment is considered.

One point patients raise a lot: contraception. The MHRA advises women using oral contraceptives to add a non-oral method, such as condoms, for the first four weeks of Mounjaro and for four weeks after each dose increase, because the medicine can reduce how well the pill is absorbed. NHS England covers this and related advice on its weight management injections page.

What does the clinical evidence show about Mounjaro and weight?

The headline evidence comes from the SURMOUNT programme. In SURMOUNT-1, which randomised 2,539 adults and ran for 72 weeks, participants on the highest 15mg dose saw average body-weight reductions of around 20 to 21%, with some analyses reaching roughly 22.5%. These are trial figures reported in the New England Journal of Medicine, achieved alongside diet and activity support, and individual results vary.

More recently, the head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4mg over 72 weeks in 751 adults with obesity and no diabetes. Tirzepatide produced greater average weight reduction. NICE's appraisal of tirzepatide reached a similar conclusion when weighing the indirect evidence. If you're weighing the two, our comparison content and the look at newer molecules like retatrutide add useful context.

It helps to read these numbers honestly. They are averages from controlled trials where participants received structured support, so they describe what's possible rather than what's promised. NICE also builds in a review point: if someone hasn't lost at least 5% of their weight after six months at the highest tolerated dose, continuing is reconsidered.

The wider tirzepatide clinical programme, combining the SURMOUNT weight trials with the SURPASS diabetes trials, involved well over 10,000 participants, which is part of why the medicine has such a substantial evidence base behind its UK licence. For the source data, the SURMOUNT-1 trial paper is the definitive read.

What are the common and serious side effects?

Most side effects are digestive and tend to show up when you start or step up a dose. Nausea is the one people notice most, along with things like diarrhoea, constipation, indigestion, burping and occasional vomiting. Tiredness, headache, dizziness and mild injection-site reactions also come up. For many people these ease within a few days to a couple of weeks as the body adjusts, and starting low is designed to keep them manageable.

There are less common but more serious signals worth knowing. On 29 January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as an infrequent but potentially serious side effect of GLP-1 medicines. The message is simple: severe, persistent stomach pain that may spread through to your back, with or without vomiting, needs urgent medical attention. Gallbladder problems, dehydration from severe vomiting or diarrhoea, allergic reactions and sudden vision changes are also reasons to seek help promptly.

Our fuller breakdown of Mounjaro side effects goes through each of these, including how to tell an expected early effect from something that needs a call. It also covers practical questions people ask, such as alcohol, which we address separately in whether you can drink on Mounjaro.

Anyone can report a suspected side effect, or a suspicious seller, through the MHRA's Yellow Card scheme. Reporting feeds directly into the safety monitoring that the Black Triangle symbol represents, so it genuinely matters. If something doesn't feel right, contacting your prescriber early is always the safer move than waiting it out.

Can you get Mounjaro on the NHS?

Yes, but access is tightly phased and the criteria are strict. NICE recommends tirzepatide (in guidance TA1026) for adults with a BMI of 35 or above plus at least one weight-related condition, with the threshold reduced by 2.5 kg/m² for the ethnic backgrounds noted earlier. The NHS is rolling it out in stages rather than all at once.

As things stand, the earliest cohort is adults with a BMI of 40 or above and four or more of five qualifying conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. From June 2026 this widened to BMI 35 to 39.9 with four or more conditions, and around March 2027 it is due to extend to BMI 40 or above with three conditions. From April 2026, GP practices may prescribe under the new GP contract, though taking part is optional, so availability varies by area and practice.

Every NHS patient also joins a wrap-around programme of diet and activity support, and meeting the criteria doesn't in itself guarantee access. NICE sets out the recommendations on its appraisal page for tirzepatide. Criteria differ in Scotland, Wales and Northern Ireland.

The honest reality is that many people don't meet these thresholds, or don't want to wait for a phase they'd qualify under. A regulated private route is the alternative for them, and our page on Mounjaro and your GP explains how the two routes fit together, including notifying your GP. None of this is a criticism of the NHS; the criteria simply reflect how a limited resource is being introduced.

What does Mounjaro cost, and how should you think about price?

Private weight-loss treatment in the UK is priced per pen or per month, and it varies between providers. Eli Lilly raised Mounjaro's UK list price from 1 September 2025, with the highest dose's list price reported to have risen from around £122 to around £330 per four-week pen. Since then, typical private prices have ranged roughly £149 to £375 a month depending on dose and provider. Those figures are reported market context, not our own pricing.

What a headline number often leaves out matters more than the number itself. A genuine price should include the consultation, the prescription, delivery and proper aftercare, and some listings quietly separate these into add-on fees. When you compare, compare the whole package. Our Mounjaro price explainer lays out what to check, and the current treatment cost sits on our treatment page.

We'll be straight with you: nume isn't the cheapest, and that's a deliberate choice. One transparent price covers your free consultation, the prescription, free next-working-day tracked delivery and priority aftercare seven days a week, with no subscription and no auto-renewals. Every repeat order is clinically re-reviewed rather than rubber-stamped.

For a prescription medicine, price is the wrong test to lead with anyway. The right questions are whether the pharmacy is genuinely regulated and whether the supply chain is legitimate. The MHRA has repeatedly warned about counterfeit weight-loss pens sold online without a prescription, some containing insulin; in 2025 around 20 million doses of illegally traded weight-loss medicines, with a street value near £45m, were seized. That's the risk cheapness can carry.

How do you access Mounjaro safely through nume?

The only lawful way to obtain Mounjaro in the UK is a prescription following a clinical assessment. Through nume that starts with a free online consultation. Your answers don't drop into a queue for software to score. A named, GPhC-registered Independent Prescriber reads them, the same day, and decides whether treatment is clinically appropriate for you.

Safety is built into the process rather than bolted on. We verify identity with photo ID, confirm your weight on a live video check, and notify your GP in line with GPhC guidance. Transfer patients are asked for evidence of their current treatment, and dose increases require supporting evidence too. It's more thorough than some routes, on purpose.

Once a prescriber approves treatment, the nume Promise kicks in: order before 12pm Monday to Friday and, if clinically approved, your treatment is dispatched the same day and delivered free the next working day by DPD, tracked, in plain unbranded packaging. You can track it on your phone like any other parcel. If you want to see who stands behind the clinical side, our clinical team profile introduces them.

Before ordering from any online pharmacy, check its registration on the GPhC register. A question our prescribers hear most weeks is whether buying online is safe at all, and the honest answer is that it can be, provided the pharmacy is verifiable and a real clinician is involved. When you're ready, you can speak to our prescribers and start your free consultation.